PBS support for Australians living with leukaemia

Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded access to a breakthrough medicine through the Pharmaceutical Benefits Scheme (PBS). From 1 December, access to Venclexta® (venetoclax) will be extended in combination with obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukaemia who have co-existing…